Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas

Oncologist

Volumn 18, Issue 12, 2013, Pages 1270-1277

  Raghav, Kanwal P S ^a   Shetty, Aditya V ^b   Kazmi, Syed M A ^a   Zhang, Nianxiang ^a   Morris, Jeffrey ^a   Taggart, Melissa ^a   Fournier, Keith ^a   Royal, Richard ^a   Mansfield, Paul ^a   Eng, Cathy ^a   Wolff, Robert A ^a   Overman, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Appendix adenocarcinoma; Celecoxib; Cetuximab; COX 2; KRAS; MSI

Indexed keywords

B RAF KINASE; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE;

ADENOCARCINOMA; ADULT; AGE; AGED; APPENDIX CANCER; ARTICLE; CANCER GRADING; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SIGNET RING CARCINOMA;

APPENDIX ADENOCARCINOMA; CELECOXIB; CETUXIMAB; COX-2; KRAS; MSI;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; APPENDICEAL NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PYRAZOLES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84890095787     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0186     Document Type: Article

References (29)

1. Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: Retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 1998;41:75-80.
2. McCusker ME, Cote TR, Clegg LX et al. Primary malignant neoplasms of the appendix: A population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer 2002;94:3307-3312.
3. Turaga KK, Pappas SG, Gamblin T. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol 2012;19:1379-1385.
4. Benedix F, Reimer A, Gastinger I et al. Primary appendiceal carcinoma-epidemiology, surgery and survival: Results of a German multi-center study. Eur J Surg Oncol 2010;36:763-771.
5. Misdraji J, Yantiss RK, Graeme-Cook FM et al. Appendiceal mucinous neoplasms: A clinicopathologic analysis of 107 cases. Am J Surg Pathol 2003; 27:1089-1103.
6. Raghav KP, Taggart MW, Fournier KF et al. Is malignant dedifferentiation for mucinous appendiceal neoplasms a valid phenomenon or merely histopathologic ambiguity? J Am Coll Surg 2011;212:906.
7. Nitecki SS, Wolff BG, Schlinkert R et al. The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg 1994;219:51-57.
8. Stewart JH 4th, Shen P, Russell GB et al. Appendiceal neoplasms with peritoneal dissemination: Outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2006;13:624-634.
9. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7:69-76.
10. Compton C, Fenoglio-Preiser CM, Pettigrew N et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000;88:1739-1757.
11. Sheehan KM, Sheahan K, O'Donoghue DP et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282: 1254-1257.
12. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532.
13. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study. J Natl Cancer Inst 1998;90:675-684.
14. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-2019.
15. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
16. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-2096.
17. Arber N, Eagle CJ, Spicak J et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-895.
18. Sheng H, Shao J, Kirkland SC et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99: 2254-2259.
19. Andreopoulou E, Yee H, Warycha MA et al. Mucinous cancer of the appendix: Challenges in diagnosis and treatment. J Chemother 2007;19:451-454.
20. Andreopoulou E, Muggia F, Safa M et al. Phase II study of cetuximab in mucinous peritoneal carcinomatosis. J Clin Oncol 2006;24(18S):14020.
21. Edge S, Byrd, DR, Compton CC. AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 7th ed. New York, NY: Springer 2010.
22. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: John Wiley & Sons 1987.
23. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-337.
24. Shetty S, Thomas P, Ramanan B et al. Kras mutations and p53 overexpression in pseudomyxoma peritonei: Association with phenotype and prognosis. J Surg Res 2013;180:97-103.
25. Zauber P, Berman E, Marotta S et al. Ki-ras gene mutations are invariably present in low-grade mucinous tumors of the vermiform appendix. Scand J Gastroenterol 2011;46:869-874.
26. Overman MJ, Fournier K, Hu CY et al. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: The prognostic impact of histological grade. Ann Surg 2013;257:1072-1078.
27. Overman MJ, George B, Taggart MW et al. The natural history and role of surgical cytoreduction and systemic chemotherapy in high-grade mucinous adenocarcinomas of the appendix. J Clin Oncol 2013;31(4S):199.
28. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 2010;7:153-162.
29. Walther A, Johnstone E, Swanton C et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9:489-499.